All In Biotech

Drug Trial Radar · NCT07821762

A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 2028

Study completion Mar 2029

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe. About 63 participants will be assigned by chance to receive either empasiprubart or placebo by intravenous infusion; all participants will also receive IVIg. The study includes screening for up to 72 hours, study treatment for the first two weeks, and follow-up through Week 67 (15 months after the last dose of study treatment). Participation lasts up to 67 weeks.

Conditions

  • Guillain-Barré Syndrome (GBS)

Interventions

  • Empasiprubart IVBiological

    Intravenous infusion of Empasiprubart

  • Empasiprubart Placebo IVOther

    Intravenous infusion of Placebo

  • Intravenous immunoglobulin (IVIg)Biological

    Intravenous infusion of IVIg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With a Guillain-Barré Syndrome Disability Scale (GBS-DS) Score ≤2 at Week 4Time frame: at week 4

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.